The modernized Orange Book system (OB) provides consumers, the Pharmaceutical industry and researchers around the world, updated information on Drug products, and their Therapeutic Equivalence under Section 505 of the Federal Food, drug and Cosmetics Act, in addition to Patent and Exclusivity data. TTI provides ongoing maintenance support and enhancements to OB, to support the users at the FDA Office of Generic Drugs, in addition to supporting external users via FDAs mobile initiative and other reporting initiatives.